Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.530
+0.170 (7.20%)
At close: Feb 6, 2026, 4:00 PM EST
2.548
+0.018 (0.73%)
After-hours: Feb 6, 2026, 7:59 PM EST
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $67.46M in the quarter ending September 30, 2025, with 15.20% growth. This brings the company's revenue in the last twelve months to $250.43M, up 175.62% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$250.43M
Revenue Growth
+175.62%
P/S Ratio
3.35
Revenue / Employee
$298,837
Employees
838
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Geron | 183.40M |
| Phathom Pharmaceuticals | 147.19M |
| ARS Pharmaceuticals | 142.77M |
| UroGen Pharma | 96.52M |
| Theravance Biopharma | 80.33M |
| Vir Biotechnology | 16.86M |
| Nanobiotix | 11.93M |
| Aktis Oncology | 5.56M |
IOVA News
- 1 day ago - Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewsWire
- 21 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Iovance Biotherapeutics: Bright Prospects For 2026 - Seeking Alpha
- 3 months ago - Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode - Seeking Alpha
- 3 months ago - Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders - GlobeNewsWire
- 4 months ago - Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play - Seeking Alpha
- 5 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire